Redcliffe Labs has announced the strategic divestment of its fertility services business, Crysta IVF, to Moon Care Private Limited, the healthcare arm of MMG Group.
The transaction reflects Redcliffe Labs’ continued focus on strengthening its diagnostics capabilities and expanding its presence in preventive and advanced diagnostic services across India. At the same time, Crysta IVF, which achieved EBITDA profitability at the start of FY26, is well-positioned to continue its growth journey under the dedicated leadership of Moon Care
Private Limited, which will further strengthen its focus on delivering specialized fertility care and expanding access to reproductive health services.
Aditya Kandoi, Founder & CEO, Redcliffe Labs, said, “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare – to add healthier years to people’s lives. This divestment allows us to sharpen that focus even further. For Dheeraj (Co-founder, Redcliffe Labs) and me, Crysta IVF has been a meaningful part of our journey. What started as an Operate & Manage model in 2021 evolved into a scalable network of high-quality, self-owned centres, achieving profitability in a relatively short time. We are proud of the foundation that has been built, and we’re confident that under Moon Care Private Limited’s leadership, Crysta IVF will continue to expand its impact in fertility care.”
Sanjeev Agarwal, Chairman, MMG Group, said, “Crysta IVF has earned the trust of thousands of families, and we see a strong opportunity to build on this foundation – expanding access to high-quality fertility treatments across the country while continuing to enhance patient experience and outcomes.”
Alvarez & Marsal acted as the exclusive advisor to the transaction.
Commenting on the transaction, Mohit Khullar, Managing Director and Leader – Corporate Finance, Alvarez & Marsal India, said: “This transaction underscores strong investor confidence in the healthcare services ecosystem and reinforces the growth potential of Crysta within the IVF segment. We are grateful to all stakeholders for their trust and collaboration in delivering a successful outcome.”
For patients already served by Crysta IVF, the transition will be seamless, with no change to ongoing operations. The existing Crysta IVF team and leadership will continue to lead the business, working closely with Moon Care, which will provide strategic guidance and mentorship. This ensures continuity of care without disruption, while also enabling the introduction of new initiatives to further enhance patient outcomes.
For Redcliffe Labs, the deal signifies a sharpened focus on the diagnostic segment. This will enable the company to accelerate expansion, increase testing volumes, and deepen its presence in preventive healthcare, driving greater impact through early detection and accessible care.
